Regulation of cell signaling pathways by Schisandrin in different cancers: Opting for "Swiss Army Knife" instead of "Blunderbuss"

Lin, Xiukun; Attar, Rükset; Mobeen, Iqra; Ishmuratova, Margarita; Aras, Aliye; Butt, Ghazala; Farooqi, Ammad Ahmad

doi:10.14715/cmb/2021.67.2.5

Cited by 5 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An analysis of the literature devoted to the study of the identified compounds from Schisándra chinénsis biological activity gave the following results. Schizandrin (Schizandrol A) and Schisantherin A (Gomisin C) exhibit antitumor, neuroprotective, immunomodulatory, antioxidant as well as with therapeutic potential to overcome multidrug resistance in cancer [51][52][53][54][55][56][57][58][59][60][61].…”

Section: Resultsmentioning

confidence: 99%

Secondary metabolites of Schisandra chinensis in homeostasis regulator adaptogen herbal formula for preventive oncology

Bocharova,

Kazeev,

Shevchenko

et al. 2023

View full text Add to dashboard Cite

The original herbal formula of homeostasis regulator Multiphytoadaptogen (MPhA) for preventive oncology developed by the N.N. Blokhin Center of Oncology containing phytocomponents from Schizandra chinensis has been investigated in vitro, in vivo and in clinical studies. The MPhA multi-target effects are achieved by optimizing the functioning of the nervous, immune and endocrine defense systems that regulate homeostasis under stress. Everything that has been previously studied for MPhA can be considered as preclinical testing, including clinical research, which can be regarded as the pilot studies. This was allowed because MPhA in Russia is registered as a parapharmaceutical agent and therefore standardized according to established requirements. However, due to the high efficiency of MPhA, a detailed study of the chemical composition and standardization of it is required, including the composition of Schisandra chinensis Baill (Schisandraceae) active components, which turned out to be translocated into MPhA as a result of the extraction technology developed. So, for MPhA identification and standardization we detected the secondary metabolites in the herbal formula MPhA as well as in fruits extract of Schisándra chinénsis using high-performance liquid chromatography in combination with mass spectrometry. Chromatography was performed on an ACQUITY UPLC BEH C18 column in a gradient mode. A TSQ Vantage triple quadrupole mass spectrometer with electrospray ionization was used. Lignans Schizandrin and Schizantherin A were identified in the MPhA as well as in Schisándra chinénsis fruits extract obtained by the technology developed. The determined secondary metabolites can be used for standardization and quality testing of the herbal formula MPhA. In addition, we performed in silico analyzes of Schizandrin and Schizantherin A biological activity spectra using computer program PASS (Prediction of Activity Spectra for Substances). Schizandrin and Schizantherin A activities, according the scientific literature and in silico analysis, correspond to the properties studied for MPhA which therefore fits into the concept of a drug – homeostasis regulator adaptogen for preventive oncology.

show abstract

Section: Resultsmentioning

confidence: 99%

Secondary metabolites of Schisandra chinensis in homeostasis regulator adaptogen herbal formula for preventive oncology

Bocharova,

Kazeev,

Shevchenko

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Анализ литературы по изучению биологической активности выделенных соединений из плодов Schisandra chinensis дал следующие результаты. Схизандрин (схизандрол А) и схизантерин А (гомизин С) обладают противоопухолевым, нейропротекторным, иммуномодулирующим, антиоксидантным действиями, а также имеют потенциал для преодоления множественной лекарственной устойчивости при раке [38][39][40][41][42][43][44][45][46][47].…”

Section: результаты и обсуждениеunclassified

Schisandrin and Schisantherin A in Multiphytoadaptogen for Preventive Oncology

Bocharova,

Kazeev,

Shevchenko

et al. 2023

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Background. The original herbal formula of Multiphytoadaptogen (MPhA) for preventive oncology developed by the N. N. Blokhin Center of Oncology containing phytocomponents from Schisandra chinensis (Turcz.) Baill (Schisandraceae), has been investigated in vitro, in vivo. Preliminary efficiency in clinical trials has also been obtained. This was allowed because MPhA in Russia is registered as a parapharmaceutical agent and therefore standardized according to established requirements. However, due to the high efficiency of MPhA, a detailed study of the chemical composition and standardization of it is required, including the Schisandra chinensis active components, which turned out to be translocated into MPhA as a result of the extraction technology developed.The aim of the study was to identify the Schisandra chinensis biologically active substances in MPhA and to evaluate the biological activity profiles of the identified phytocomponents using in silico analysis.Materials and methods. we used high performance liquid chromatography in combination with mass spectrometry (HPLC–MS / MS). Chromatography was performed on an ACQUITY UPLC BEH C18 column in a gradient mode. A TSQ Vantage triple quadrupole mass spectrometer with electrospray ionization was used. we performed in silico analyzes of Schisandrin and Schisantherin A biological activity spectra using computer programs PASS and PharmaExpert.Result. The secondary metabolites lignans Schisandrin and Schisantherin A were identified in the herbal formula MPhA. Schisandrin and Schisantherin A activities, according the scientific literature and in silico analysis, correspond to the properties studied for MPhA which therefore fits into the concept of medication for preventive oncology.Conclusion. The determined secondary metabolites can be used for identification, standardization and quality testing of the herbal formula MPhA.

show abstract

“…Natural product research has generated wealth of information about significance of pharmacologically active compounds from natural sources [10,20,27,34,38,47].…”

Section: Use Of Natural Products In the Treatment Of Cerebral/ischemi...mentioning

confidence: 99%

Cerebral ischemia reperfusion injury: from public health perspectives to mechanisms

Kapanova¹,

Tashenova²,

Akhenbekova³

et al. 2022

View full text Add to dashboard Cite

Cerebral ischemia/reperfusion injury has emerged as an intricate mechanism. However, identification of wide-ranging mechanisms which mechanistically regulate reperfusion injuries have significantly improved our understanding. Recent advancements in our knowledge about the molecular consequences of ischemia and reperfusion might be advantageous in the development of innovative therapeutic strategies for the treatment of patients with ischemia and reperfusionassociated organ dysfunction and tissue inflammation. Some of the extensively studied mechanisms of reperfusion injury consist of oxidative stress, mitochondrial mechanisms, infiltration of leukocytes, activation/aggregation of the platelets, complement activation, and disruption of the blood-brain-barrier (BBB), which eventually results in the brain oedema or haemorrhagic transformations. In this review, we have attempted to provide a review of the protein networks involved in the regulation of cerebral ischemia reperfusion injury and how different natural products have shown potential in the amelioration of reperfusion induced injuries.

show abstract

Regulation of cell signaling pathways by Schisandrin in different cancers: Opting for "Swiss Army Knife" instead of "Blunderbuss"

Cited by 5 publications

References 56 publications

Secondary metabolites of Schisandra chinensis in homeostasis regulator adaptogen herbal formula for preventive oncology

Secondary metabolites of Schisandra chinensis in homeostasis regulator adaptogen herbal formula for preventive oncology

Schisandrin and Schisantherin A in Multiphytoadaptogen for Preventive Oncology

Cerebral ischemia reperfusion injury: from public health perspectives to mechanisms

Contact Info

Product

Resources

About